Biomarker-Guided Adjuvant Therapy in Stage II/III Colon Cancer: A Systematic Review of Current Evidence and Clinical Implications.
Personalizing colon cancer treatment using tumor biomarkers and blood tests helps doctors spare patients from harsh chemotherapy while maintaining cure rates.
This PRISMA-guided systematic review of 52 studies consolidates evidence for biomarker-driven adjuvant therapy in stages II/III colon cancer, highlighting that dMMR tumors now have phase 3 evidence for checkpoint inhibitor benefit and that ctDNA-guided de-escalation safely reduces oxaliplatin exposure. The review proposes a stepwise clinical framework from universal MMR testing to dynamic ctDNA monitoring, while identifying persistent gaps in elderly patients and under-represented ethnic populations.
What the study was
- Study design
- systematic_review
- Category
- precision oncology
- Maturity
- Potentially Practice-Changing
- Journal
- Cancer Investigation
Why it surfaced
Comprehensive systematic review synthesizing landmark trials (ATOMIC, DYNAMIC-III, NICHE-2) reshaping adjuvant CRC treatment. Proposes stepwise biomarker framework: universal MMR → CEA → mutational profiling → selective ctDNA. Cross-topic relevance for ctDNA/liquid biopsy (T3) and precision oncology (T5).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.